Form 4: Rapport Therapeutics CSO Sells Shares

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock for approximately $127,000 through a pre-arranged 10b5-1 trading plan.

Summary

• David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP), reported the sale of company common stock.
• On August 15, 2025, Bredt sold a total of 8,500 shares.
• The sales included 8,300 shares at a weighted average price of $14.9769, and 200 shares at a weighted average price of $15.79.
• The total proceeds from these sales amount to approximately $127,000.
• Following these transactions, Bredt directly beneficially owns 426,642 shares of common stock.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024.

Sentiment

Score: 5

Explanation: A neutral score. While an insider sale can be perceived negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns that it's based on new, adverse information. It's a routine personal financial management event.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct equity stake in the company.

Future Outlook

NA

Industry Context

This is a routine insider transaction for a biotechnology company. Such sales are common for executives managing personal finances or diversifying portfolios, especially when pre-planned.

Comparison to Industry Standards

• Insider sales via 10b5-1 plans are standard practice across industries, including biotechnology, for executives to liquidate shares in a compliant manner. This filing does not provide specific comparable companies or projects to detail.

Stakeholder Impact

• Shareholders: The sale slightly reduces the Chief Scientific Officer's direct ownership, which could be interpreted as a minor decrease in alignment, though mitigated by the 10b5-1 plan.

Key Dates

Recommendation

The filing is a routine Form 4 detailing a pre-planned insider stock sale. It does not contain new material information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The sale is part of a 10b5-1 plan, which suggests it's for personal financial management rather than a signal of negative company prospects. Therefore, a "hold" recommendation is appropriate as this filing alone does not provide a basis for a buy or sell decision.

Keywords

Rapport Therapeutics, RAPP, Insider Trading, Form 4, David Bredt, Chief Scientific Officer, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals